Human RARB

retinoic acid receptor, beta

By David Laperriere, Marieke Rozendaal, and Sylvie Mader

Classification	Homo sapiens » Zinc-coordinating Group » Hormone-nuclear Receptor Family » Subfamily 1 (TR, RAR, PPAR, REV-ERB, E78, RZR/ROR, CNR14, ECR, VDR, DHR96, NHR1, and 27 individual genes)
Related TF(s)	(none defined here)
Homologs	• Rarb
Links	ENSG00000077092 (Ensembl) 5915 (Entrez Gene) Homologene 180220 (OMIM)
Synonyms	RRB2, NR1B2, HAP

The article completion score for this TF is 89%. Refresh score »
Download scoring guide and see what's missing »

Summary Structure TFBS Targets Protein Interactions Genetics Expression Ontologies Papers

view content comments

Download article (PDF)

Download data (Excel)

View recent activity

Genetics

Homozygous RAR beta mutants in mouse are growth-deficient, but are fertile and have a normal longevity. They display homeotic transformations and malformations of cervical vertebrae and a retrolenticular membrane. RAR beta is apparently functionally redundant with either RAR alpha or RAR gamma in mouse knock-out models. RAR alpha/RAR beta double mutants display numerous visceral abnormalities, most of which are incompatible with post-natal life.RAR beta/RAR gamma double mutants show major ocular defects including a shortening of the ventral retina and pre-natal retinal dysplasia.^[1]^[2]

References

Luo J et al. Mice lacking all isoforms of retinoic acid receptor beta develop normally and are susceptible to the teratogenic effects of retinoic acid. Mech. Dev., 53(1):61-71. (PMID 8555112)

Ghyselinck NB et al. Role of the retinoic acid receptor beta (RARbeta) during mouse development. Int. J. Dev. Biol., 41(3):425-47. (PMID 9240560)

MeSH cloud (automatically populated)

Key terms All terms Cloud

About this section

The MeSH cloud below displays MeSH terms that are associated with this transcription factor. The physical size of the terms reflect the significance of their association with the transcription factor as determined by the Fisher's Exact Test. It should be noted that these associations do not necessarily imply a positive correlation between the described MeSH term and this transcription factor. For instance, if the MeSH term "apoptosis" occurs, it may indicate that this transcription factor can induce apoptosis (positive correlation), or prevent apoptosis (negative correlation). Methods: The transcription factor is mapped to a set of Pubmed publications through the gene-to-pubmed association as provided by NCBI. Then, a collection of MeSH terms associated with the papers are compiled, along with the frequency of each MeSH term. The Fisher's Exact Test is conducted on the frequency of each term in the collection, versus its average frequency, to determine its significance in the collection. More information on MeSH can be found on the MeSH homepage.

	MeSH term	Fisher's exact p-value
1	Breast Neoplasms	2.7 x 10^-11
2	Carcinoma, Hepatocellular	1.0 x 10^-8
3	Leukemia, Promyelocytic, Acute	3.0 x 10^-8
4	Esophageal Neoplasms	3.6 x 10^-8
5	Carcinoma, Squamous Cell	4.5 x 10^-8
6	Prostatic Neoplasms	5.6 x 10^-5
7	Uterine Cervical Neoplasms	0.00021
8	Lipodystrophy, Familial Partial	0.00025
9	Neoplasm Invasiveness	0.0016
10	Choroid Plexus Neoplasms	0.0029
11	Kuru	0.0032
12	Teratocarcinoma	0.0034
13	Microsatellite Instability	0.0039
14	Carcinoma, Small Cell	0.0039
15	Carcinoma, Renal Cell	0.0042
16	Prostatic Intraepithelial Neoplasia	0.0052
17	Progeria	0.0055
18	Carcinoma, Adenosquamous	0.0067
19	Carcinoma, Endometrioid	0.0082
20	Disease Progression	0.010
21	Blast Crisis	0.011
22	Thyroid Neoplasms	0.014
23	Carcinoma, Lobular	0.015
24	Endometrial Hyperplasia	0.015
25	Leukoplakia, Oral	0.016
26	Metaplasia	0.016
27	Primary Myelofibrosis	0.024
28	Oropharyngeal Neoplasms	0.024
29	Creutzfeldt-Jakob Syndrome	0.028
30	Tobacco Use Disorder	0.031
31	Genetic Predisposition to Disease	0.038
32	Lymphatic Metastasis	0.041
33	Colonic Neoplasms	0.044

	MeSH term	Fisher's exact p-value
1	Neoplasms	6.2 x 10^-36
2	Neoplasms by Site	1.2 x 10^-34
3	Carcinoma	1.2 x 10^-23
4	Neoplasms, Glandular and Epithelial	2.8 x 10^-22
5	Neoplasms by Histologic Type	5.5 x 10^-20
6	Breast Neoplasms	2.7 x 10^-11
7	Digestive System Neoplasms	6.5 x 10^-11
8	Breast Diseases	6.6 x 10^-11
9	Head and Neck Neoplasms	1.9 x 10^-10
10	Neoplasms, Squamous Cell	7.7 x 10^-10
11	Adenocarcinoma	9.6 x 10^-10
12	Urogenital Neoplasms	6.9 x 10^-9
13	Carcinoma, Hepatocellular	1.0 x 10^-8
14	Leukemia, Promyelocytic, Acute	3.0 x 10^-8
15	Esophageal Neoplasms	3.6 x 10^-8
16	Carcinoma, Squamous Cell	4.5 x 10^-8
17	Neoplastic Processes	5.2 x 10^-7
18	Gastrointestinal Neoplasms	1.0 x 10^-6
19	Respiratory Tract Neoplasms	1.2 x 10^-6
20	Lung Neoplasms	1.7 x 10^-6
21	Liver Neoplasms	2.6 x 10^-6
22	Leukemia, Myeloid	3.0 x 10^-6
23	Thoracic Neoplasms	1.1 x 10^-5
24	Uterine Neoplasms	1.4 x 10^-5
25	Esophageal Diseases	1.9 x 10^-5
26	Genital Neoplasms, Female	3.0 x 10^-5
27	Skin Diseases	3.6 x 10^-5
28	Precancerous Conditions	3.8 x 10^-5
29	Prostatic Neoplasms	5.6 x 10^-5
30	Leukemia, Myeloid, Acute	6.3 x 10^-5
31	Uterine Diseases	6.6 x 10^-5
32	Prostatic Diseases	0.00014
33	Uterine Cervical Neoplasms	0.00021
34	Genital Neoplasms, Male	0.00023
35	Lipodystrophy, Familial Partial	0.00025
36	Digestive System Diseases	0.00030
37	Uterine Cervical Diseases	0.00032
38	Cell Transformation, Neoplastic	0.00033
39	Skin and Connective Tissue Diseases	0.00038
40	Leukemia	0.00056
41	Myeloproliferative Disorders	0.00092
42	Neoplasm Metastasis	0.00093
43	Neoplasm Invasiveness	0.0016
44	Endometrial Neoplasms	0.0019
45	Genital Diseases, Female	0.0021
46	Leukemia, Myelogenous, Chronic, BCR-ABL Positive	0.0024
47	Choroid Plexus Neoplasms	0.0029
48	Kuru	0.0032
49	Teratocarcinoma	0.0034
50	Gastrointestinal Diseases	0.0035
51	Microsatellite Instability	0.0039
52	Carcinoma, Small Cell	0.0039
53	Carcinoma, Renal Cell	0.0042
54	Prostatic Intraepithelial Neoplasia	0.0052
55	Liver Diseases	0.0054
56	Progeria	0.0055
57	Bone Marrow Diseases	0.0056
58	Carcinoma, Adenosquamous	0.0067
59	Pharyngeal Neoplasms	0.0070
60	Carcinoma, Endometrioid	0.0082
61	Pathologic Processes	0.0094
62	Disease Progression	0.010
63	Genital Diseases, Male	0.011
64	Blast Crisis	0.011
65	Thyroid Neoplasms	0.014
66	Carcinoma, Lobular	0.015
67	Urologic Neoplasms	0.015
68	Endometrial Hyperplasia	0.015
69	Leukoplakia, Oral	0.016
70	Metaplasia	0.016
71	Cerebral Ventricle Neoplasms	0.018
72	Lipodystrophy	0.019
73	Bronchial Neoplasms	0.020
74	Lung Diseases	0.020
75	Leukoplakia	0.023
76	Primary Myelofibrosis	0.024
77	Oropharyngeal Neoplasms	0.024
78	Creutzfeldt-Jakob Syndrome	0.028
79	Genomic Instability	0.029
80	Mouth Neoplasms	0.030
81	Tobacco Use Disorder	0.031
82	Kidney Neoplasms	0.031
83	Pharyngeal Diseases	0.034
84	Ovarian Neoplasms	0.036
85	Genetic Predisposition to Disease	0.038
86	Lymphatic Metastasis	0.041
87	Intestinal Neoplasms	0.043
88	Colonic Neoplasms	0.044
89	Otorhinolaryngologic Neoplasms	0.049

MGI mammalian phenotype terms (automatically populated)

About this section

Data displayed in this section is derived from the Mouse Genome Database (MGD). For more information, see Eppig JT, Bult CJ, Kadin JA, Richardson JE, Blake JA, and the members of the Mouse Genome Database Group. 2005. The Mouse Genome Database (MGD): from genes to mice-a community resource for mouse biology. Nucleic Acids Res 2005; 33: D471-D475.

Links

Links for this section Links for other sections

There are no links here... Yet.